The Board of Directors of the Genetico Center for Genetics and Reproductive Medicine approved the share price for the IPO on the Moscow Exchange at RUB 17.88 per share.
The company will offer 10 million shares to investors, which is 12% of the company’s capital. Trading will begin on April 25, 2023, the company’s ticker on the Moscow Exchange is GECO. Issue registration number: 1-01-87198-H.
In accordance with the law, investors can submit applications to purchase shares and participate in the IPO to any broker in writing or orally from April 12. Ordered shares will be issued on the Moscow Exchange from 10 AM on April 25. The minimum lot is 10 shares. Orders will only be taken until the issue is completed.
The offering is organized by ALOR with IVA Partners as the co-organizer. For more information, please visit the issuer’s website or contact the organizers.
Genetico Center is a resident of Skolkovo, the Medtech Moscow Technopark of the Moscow Center for Innovative Technologies in Healthcare, a subsidiary of the Human Stem Cell Institute (HSCI— MOEX: ISKJ). The company works in the field of medical genetics and genetic research, implementing into medical practice innovative solutions for the diagnosis, prevention, and treatment of genetic and socially significant diseases.
Genetico plans to use the funds raised during its IPO to develop genetic services in Russia, enter foreign markets, register its own test kits, as well as create candidate gene therapy drugs for the treatment of orphan diseases.
Genetico Center is an experienced team and a modern research and production complex that includes laboratories equipped with the latest high-performance sequencers and state-of-the-art robotic equipment, allowing them to conduct advanced genetic research in the field of medicine, genomics, and proteomics.